Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13204030 | 1.00 | MAPT (0.64) | MAPTLMNAMAPK1ALDH1A1GAA | |
| SCHEMBL2654136 | 1.00 | MAPT (0.64) | MAPTLMNAMAPK1ALDH1A1GAA | |
| SCHEMBL2654782 | 0.88 | MAPT (0.62) | MAPTLMNAMAPK1ALDH1A1GAA | |
| SCHEMBL2656807 | 0.88 | MAPT (0.62) | MAPTLMNAMAPK1ALDH1A1GAA | |
| SCHEMBL2654399 | 0.87 | MAPT (0.61) | MAPTLMNAMAPK1ALDH1A1GAA | |
| SCHEMBL2654401 | 0.87 | MAPT (0.61) | MAPTLMNAMAPK1ALDH1A1GAA | |
| SCHEMBL2654183 | 0.87 | MAPT (0.58) | MAPTLMNAMAPK1ALDH1A1GAA | |
| SCHEMBL13203996 | 0.87 | MAPT (0.58) | MAPTLMNAMAPK1ALDH1A1GAA | |
| SCHEMBL2654181 | 0.87 | MAPT (0.58) | MAPTLMNAMAPK1ALDH1A1GAA | |
| SCHEMBL2970798 | 0.87 | MAPT (0.55) | MAPTLMNAMAPK1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017077307-A1 | THERAPY AND PHARMACEUTICAL COMPOSITION | UNIVERSITY OF SOUTHAMPTON (GB) | 2017-05-11 | — | — | WO | claimed |
| WO-2017077307-A1 | THERAPY AND PHARMACEUTICAL COMPOSITION | UNIVERSITY OF SOUTHAMPTON (GB) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017077307-A1 | THERAPY AND PHARMACEUTICAL COMPOSITION | UNIVERSITY OF SOUTHAMPTON (GB) | 2017-05-11 | — | — | WO | disclosed |
| US-8410087-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| EP-2508524-A2 | Indole compound | Takeda Pharmaceutical Company Limited (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-7777047-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20100144702-A1 | INDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100137610-A1 | Indole compound | YASUMA TSUNEO | 2010-06-03 | — | — | US | disclosed |
| US-7718798-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7652133-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090286975-A1 | Indole compound | YASUMA TSUNEO | 2009-11-19 | — | — | US | disclosed |
| US-20080096877-A1 | Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144702-A1 | INDOLE COMPOUND | GCKR, GPR119, SLC5A1 | MAPT 4224/4885LMNA 4727/4885MAPK1 380/4885 |
| US-20100137610-A1 | Indole compound | GCKR, GPR119, SLC5A1 | MAPT 4224/4885LMNA 4727/4885MAPK1 380/4885 |
| US-20090286975-A1 | Indole compound | GCKR, GPR119, SLC5A1 | MAPT 4224/4885LMNA 4727/4885MAPK1 380/4885 |
| US-20080096877-A1 | Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example | GCKR, GCK, KHK | MAPT 4496/4885LMNA 4653/4885MAPK1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.